| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Barclays analyst Andrew Mok maintains Tenet Healthcare (NYSE:THC) with a Overweight and raises the price target from $229 to...
JP Morgan analyst Benjamin Rossi maintains Tenet Healthcare (NYSE:THC) with a Overweight and raises the price target from $2...
Wells Fargo analyst Stephen Baxter maintains Tenet Healthcare (NYSE:THC) with a Overweight and raises the price target from ...
Health insurer stocks fell after the Senate ended the shutdown without extending ACA subsidies, delaying the decision to Decemb...
Truist Securities analyst David Macdonald reiterates Tenet Healthcare (NYSE:THC) with a Buy and raises the price target from...
RBC Capital analyst Ben Hendrix maintains Tenet Healthcare (NYSE:THC) with a Outperform and raises the price target from $23...